Close Menu

cell-free DNA

The distributors will promote Trovagene's clinical test services, and will also gain access to the research-use kits the firm is co-developing with Boreal Genomics.

Members of the health plan will have access to Biocept's growing menu of circulating tumor cell and circulating tumor DNA tests.

A team from Mount Sinai and Swift Biosciences used targeted sequencing to detect cancer mutations in uterine lavage fluid.

Investigators will compare results using Biocept's platform in cerebrospinal fluid to current standard methods for diagnosing leptomeningeal metastases.

University of Cambridge researchers found that the portion of tumor DNA in patients' blood could predict treatment response and time to disease progression.

The results confirmed that circulating mutations can be reliably detected and changed during treatment, and showed that they could be a valuable prognostic biomarker.

Natera will design a personalized liquid biopsy assay for each patient and will test its ability to monitor disease progression and treatment response. 

The company is planning to work with up to 40 sites, with an initial goal of sequencing circulating cell-free DNA from 10,000 people.

The goal of the Texas team is to identify methylation signatures that can help with prognosis and be used to develop noninvasive tests to monitor disease progression.

Clinical MDx firm OmniSeq has been an early-access user of the research-use-only assay and is working on validating it to predict checkpoint inhibitor response.

Pages

At a meeting this week, researchers and others discussed the regulatory oversight needed for germline genome editing.

The US Food and Drug Administration has asked questions about Myriad Genetics' GeneSight test, according to Bloomberg.

Researchers report that neutrophil extracellular traps appear to binds gallstones together, according to New Scientist.

In Science this week: approach to infer genotype-by-environment interaction from genetic variants associated with phenotypic variability, and more.